
Michael D. Pak
Examiner (ID: 18380)
| Most Active Art Unit | 1646 |
| Art Unit(s) | 1621, 1674, 1812, 1646, 0 |
| Total Applications | 1534 |
| Issued Applications | 702 |
| Pending Applications | 283 |
| Abandoned Applications | 564 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15931195
[patent_doc_number] => 20200157231
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-21
[patent_title] => DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-LGR7 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 16/782728
[patent_app_country] => US
[patent_app_date] => 2020-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24920
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782728
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/782728 | DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-LGR7 ANTIBODY | Feb 4, 2020 | Abandoned |
Array
(
[id] => 19551096
[patent_doc_number] => 12134795
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-05
[patent_title] => Sensor for cyanuric acid detection
[patent_app_type] => utility
[patent_app_number] => 16/750465
[patent_app_country] => US
[patent_app_date] => 2020-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 7241
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16750465
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/750465 | Sensor for cyanuric acid detection | Jan 22, 2020 | Issued |
Array
(
[id] => 15866233
[patent_doc_number] => 20200140520
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => IMMUNOSUPPRESSIVE TGF-B SIGNAL CONVERTER
[patent_app_type] => utility
[patent_app_number] => 16/743987
[patent_app_country] => US
[patent_app_date] => 2020-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15914
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16743987
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/743987 | IMMUNOSUPPRESSIVE TGF-B SIGNAL CONVERTER | Jan 14, 2020 | Pending |
Array
(
[id] => 16420527
[patent_doc_number] => 20200345725
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-05
[patent_title] => Methods and Compositions for Treating Cancer
[patent_app_type] => utility
[patent_app_number] => 16/740187
[patent_app_country] => US
[patent_app_date] => 2020-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 121097
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -67
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16740187
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/740187 | Methods and Compositions for Treating Cancer | Jan 9, 2020 | Abandoned |
Array
(
[id] => 19275489
[patent_doc_number] => 12025612
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-02
[patent_title] => Brown adipocyte progenitors in human skeletal muscle
[patent_app_type] => utility
[patent_app_number] => 16/713048
[patent_app_country] => US
[patent_app_date] => 2019-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 16
[patent_no_of_words] => 10156
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16713048
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/713048 | Brown adipocyte progenitors in human skeletal muscle | Dec 12, 2019 | Issued |
Array
(
[id] => 16087059
[patent_doc_number] => 20200197516
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => Antagonists of Products of the HS.459642 Unigene Cluster for the Inhibition of Proliferation, Development or Differentiation of Stem Cells Including Cancer Stem Cells
[patent_app_type] => utility
[patent_app_number] => 16/685279
[patent_app_country] => US
[patent_app_date] => 2019-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11537
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685279
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/685279 | Antagonists of Products of the HS.459642 Unigene Cluster for the Inhibition of Proliferation, Development or Differentiation of Stem Cells Including Cancer Stem Cells | Nov 14, 2019 | Abandoned |
Array
(
[id] => 16837952
[patent_doc_number] => 20210145964
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => STROMA-TARGETING TREATMENT FOR PATIENTS WITH ELEVATED ADAM12 LEVELS
[patent_app_type] => utility
[patent_app_number] => 16/685100
[patent_app_country] => US
[patent_app_date] => 2019-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15399
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685100
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/685100 | STROMA-TARGETING TREATMENT FOR PATIENTS WITH ELEVATED ADAM12 LEVELS | Nov 14, 2019 | Abandoned |
Array
(
[id] => 16091393
[patent_doc_number] => 20200199683
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => METHODS FOR EVALUATING AND TREATING WALDENSTROM'S MACROGLOBULINEMIA
[patent_app_type] => utility
[patent_app_number] => 16/684193
[patent_app_country] => US
[patent_app_date] => 2019-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19237
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684193
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/684193 | METHODS FOR EVALUATING AND TREATING WALDENSTROM'S MACROGLOBULINEMIA | Nov 13, 2019 | Abandoned |
Array
(
[id] => 15893501
[patent_doc_number] => 20200146269
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => METHODS AND COMPOSITIONS FOR MODULATING INNATE LYMPHOID CELL PATHOGENIC EFFECTORS
[patent_app_type] => utility
[patent_app_number] => 16/681050
[patent_app_country] => US
[patent_app_date] => 2019-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51138
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16681050
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/681050 | Methods and compositions for modulating innate lymphoid cell pathogenic effectors | Nov 11, 2019 | Issued |
Array
(
[id] => 17385923
[patent_doc_number] => 20220033775
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => EXPANSION OF TILS UTILIZING AKT PATHWAYS INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/290639
[patent_app_country] => US
[patent_app_date] => 2019-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 146954
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290639
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/290639 | Expansion of TILs utilizing AKT pathways inhibitors | Nov 3, 2019 | Issued |
Array
(
[id] => 17385923
[patent_doc_number] => 20220033775
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => EXPANSION OF TILS UTILIZING AKT PATHWAYS INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/290639
[patent_app_country] => US
[patent_app_date] => 2019-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 146954
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290639
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/290639 | Expansion of TILs utilizing AKT pathways inhibitors | Nov 3, 2019 | Issued |
Array
(
[id] => 17334562
[patent_doc_number] => 20220000893
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => METHOD FOR TREATING T-HELPER TYPE 2 MEDIATED DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/289413
[patent_app_country] => US
[patent_app_date] => 2019-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15184
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289413
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/289413 | METHOD FOR TREATING T-HELPER TYPE 2 MEDIATED DISEASE | Oct 29, 2019 | Abandoned |
Array
(
[id] => 15524819
[patent_doc_number] => 20200054715
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-20
[patent_title] => TREATMENT OF COLLAGEN DEFECTS USING PROTEIN SOLUTIONS
[patent_app_type] => utility
[patent_app_number] => 16/665975
[patent_app_country] => US
[patent_app_date] => 2019-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18144
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16665975
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/665975 | Treatment of collagen defects using protein solutions | Oct 27, 2019 | Issued |
Array
(
[id] => 16296349
[patent_doc_number] => 20200282072
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 16/655716
[patent_app_country] => US
[patent_app_date] => 2019-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34205
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16655716
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/655716 | ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS | Oct 16, 2019 | Abandoned |
Array
(
[id] => 20242115
[patent_doc_number] => 12422427
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-23
[patent_title] => Compounds for treatment of diseases and methods of screening therefor
[patent_app_type] => utility
[patent_app_number] => 16/653874
[patent_app_country] => US
[patent_app_date] => 2019-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 55
[patent_no_of_words] => 40047
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 133
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16653874
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/653874 | Compounds for treatment of diseases and methods of screening therefor | Oct 14, 2019 | Issued |
Array
(
[id] => 19076702
[patent_doc_number] => 11946053
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-02
[patent_title] => Methods for overcoming glucocorticoid resistance and for determining glucocorticoid resistance potential in cancer
[patent_app_type] => utility
[patent_app_number] => 16/590588
[patent_app_country] => US
[patent_app_date] => 2019-10-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 34
[patent_no_of_words] => 18113
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16590588
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/590588 | Methods for overcoming glucocorticoid resistance and for determining glucocorticoid resistance potential in cancer | Oct 1, 2019 | Issued |
Array
(
[id] => 18980355
[patent_doc_number] => 11905515
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-20
[patent_title] => Chimeric antigen receptors and methods of use
[patent_app_type] => utility
[patent_app_number] => 16/579082
[patent_app_country] => US
[patent_app_date] => 2019-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 29312
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16579082
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/579082 | Chimeric antigen receptors and methods of use | Sep 22, 2019 | Issued |
Array
(
[id] => 17015254
[patent_doc_number] => 11084881
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-10
[patent_title] => Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/578987
[patent_app_country] => US
[patent_app_date] => 2019-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 104
[patent_figures_cnt] => 147
[patent_no_of_words] => 80239
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16578987
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/578987 | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof | Sep 22, 2019 | Issued |
Array
(
[id] => 16961603
[patent_doc_number] => 20210213102
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => NOVEL INTERLEUKIN-2 AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/059539
[patent_app_country] => US
[patent_app_date] => 2019-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17643
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17059539
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/059539 | NOVEL INTERLEUKIN-2 AND USE THEREOF | Sep 19, 2019 | Pending |
Array
(
[id] => 17344983
[patent_doc_number] => 20220011314
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-13
[patent_title] => IN VITRO DIAGNOSTIC ASSAY METHODS
[patent_app_type] => utility
[patent_app_number] => 17/273641
[patent_app_country] => US
[patent_app_date] => 2019-09-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10242
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17273641
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/273641 | IN VITRO DIAGNOSTIC ASSAY METHODS | Sep 4, 2019 | Pending |